REG - ValiRx PLC - Licensing Agreement with Dominion Biotech Ltd

ValiRxAnnouncement

Today 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250804:nRSD8017Ta&default-theme=true

RNS Number : 8017T  ValiRx PLC  04 August 2025

4 August 2025

ValiRx PLC

("ValiRx" or the "Company")

 

ValiRx Licensing Agreement with Dominion Biotech Ltd

London, UK - ValiRx Plc (AIM: VAL), a life sciences company focusing on
early-stage cancer therapeutics and women's health, is pleased to provide the
following update on the commercial activity of its solely owned subsidiary
Inaphaea BioLabs ("Inaphaea").

Inaphaea is pleased to announce the execution of an exclusive licence
agreement (the "Agreement") with UK based Dominion Biotech Ltd ("Dominion")
for Inaphaea's PredictRx® platform. PredictRx is a personalised cancer
screening service whereby a patient's tumour sample is processed into Patient
Derived Cells (PDCs) and subjected to a comprehensive drug combination
screening panel to determine optimal chemotherapy treatment protocols.

Under the terms of the Agreement, Inaphaea will receive a 50% share of global
net revenues from the PredictRx service to be offered by Dominion. Dominion
and Inaphaea will also share ownership of any new Patient Derived Cells (PDCs)
developed.  The Agreement is for a period of 2 years with annual renewal
thereafter. Either party may initiate a buyout of the rights of the other
party after an initial period of 18 months under pre-agreed terms based on a
multiple of trailing net revenue. Although initial revenues under the
Agreement are expected to be modest, the arrangement is strategically
important in demonstrating the commercial application of ValiRx's platform and
establishing future buyout value.

Mark Eccleston, CEO of ValiRx commented "We have expanded our relationship
with Dominion as we continue to develop and commercialise Inaphaea's asset
base. PredictRx is a pioneering, in-vitro approach for predicting drug
sensitivity for cancer therapies at the individual patient level based on
analysis of the patient's own cancer cells. This can deliver significant
benefit by identifying the most effective treatment options leading to a truly
personalised approach to therapy which ultimately should deliver improved
outcomes for patients. Inaphaea's focus is translational drug development
services and monetising of its biobank through its PDC models and through this
license to Dominion which will develop and commercialise the PredictRx
clinical service globally."

 

Anthony Holmes, CEO of Dominion commented "We're delighted to expand our
successful partnership with Inaphaea by bringing the PredictRx platform to
market globally. This innovative personalised cancer screening service
represents a significant advancement in precision oncology - using a patient's
own cancer cells to identify the most effective treatment options before
therapy begins. By leveraging our established network of oncologists and
patient-derived cell expertise, we can now offer clinicians and patients a
powerful tool to optimise treatment decisions from day one. This licensing
agreement demonstrates our commitment to translating cutting-edge science into
real-world clinical benefits that can improve patient outcomes and potentially
reduce the trial-and-error approach that too often characterises cancer
treatment today."

 

 

The Directors of the Company take responsibility for this announcement.

*** ENDS ***

Engage with the ValiRx management team directly by asking questions, watching
video
summaries and seeing what other shareholders have to say. Navigate to
our Interactive Investor
hub here: https://valirx.com/s/cc8ef3

For more information, please contact:

 Investor questions on this announcement           https://valirx.com/link/yVwQZe

 We encourage all investors to share questions

 on this announcement via our investor hub
 ValiRx plc                                        Tel: +44 115 784 0026

                                                   www.valirx.com (http://www.valirx.com)

 Dr Mark Eccleston, CEO                            Mark.Eccleston@valirx.com

 Cairn Financial Advisers LLP (Nominated Adviser)  Tel: +44 (0) 20 7213 0880

 Liam Murray / Ludovico Lazzaretti

 Shard Capital Partners LLP (Sole Broker)          Tel: +44 (0) 20 7186 9000

 Damon Heath

 V Formation (Public Relations)                    +44 (0) 115 787 0206

                                                   www.vformation.biz (http://www.vformation.biz)

 Lucy Wharton - Senior PR Executive

 Sue Carr - Director                               lucy@vformation.biz

                                                   sue@vformation.biz

Subscribe to our news alert service: https://valirx.com/s/f298d1
(https://valirx.com/s/f298d1)

 

Notes for Editors

About ValiRx

ValiRx is a life science company focused on early-stage cancer therapeutics
and women's health, accelerating the translation of innovative science into
impactful medicines to improve patient lives.

ValiRx provides the scientific, financial, and commercial framework for
enabling rapid translation of innovative science into clinical development.

Using its extensive and proven experience in research and drug development,
the team at ValiRx selects and incubates promising novel drug candidates and
guides them through an optimised process of development, from pre-clinical
studies to clinic and investor-ready assets.

ValiRx connects diverse disciplines across scientific, technical, and
commercial domains, with the aim of achieving a more streamlined, less costly,
drug development process. The team works closely with carefully selected
collaborators and leverages the combined expertise required for science to
advance.

Lead candidates from ValiRx's portfolio are outlicensed or partnered with
investors through ValiRx subsidiary companies for further clinical development
and commercialisation.

ValiRx listed on the AIM Market of the London Stock Exchange in October 2006
and trades under the ticker symbol: VAL.

For further information, visit: www.valirx.com (http://www.valirx.com)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  UPDBXLLBEVLEBBV